You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Erlotinib

Showing 1 - 25 of 1,027
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Liver Cancer Trial in Houston (Bevacizumab, Erlotinib)

Completed
Has Results
  • Liver Cancer
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Nov 3, 2022

Adult Solid Tumor Trial in Rochester (Erlotinib Hydrochloride, Irinotecan Hydrochloride)

Active, not recruiting
  • Adult Solid Neoplasm
  • Erlotinib Hydrochloride
  • Irinotecan Hydrochloride
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 12, 2023

EGFR Positive NSCLC Trial in Goyang-Si (Erlotinib plus Bevacizumab, Erlotinib)

Active, not recruiting
  • EGFR Positive Non-small Cell Lung Cancer
  • Erlotinib plus Bevacizumab
  • Erlotinib
  • Goyang-Si, Gyeonggi-do, Korea, Republic of
    National Cancer Center
Apr 4, 2022

Solid Tumors, Advanced Solid Tumors, Metastatic Cancer Trial in Korea, Republic of (bevacizumab, erlotinib)

Recruiting
  • Solid Tumors
  • +2 more
  • Daejeon, Chungcheongnam-do, Korea, Republic of
  • +9 more
Jun 6, 2023

NSCLC Trial (30 µg OBI-833/100 µg OBI-821, Erlotinib (150 mg daily))

Not yet recruiting
  • Non-small Cell Lung Cancer
  • 30 μg OBI-833/100 μg OBI-821
  • Erlotinib (150 mg daily)
  • (no location specified)
Jun 28, 2022

Lung Cancer Trial in Houston (DOTAP:Chol-TUSC2, Erlotinib, Dexamethasone)

Terminated
  • Lung Cancer
  • Houston, Texas
    UT MD Anderson Cancer Center
Feb 11, 2022

NSCLC Stage II, NSCLC, Stage IIIA Trial in Goyang-si (Erlotinib)

Active, not recruiting
  • NSCLC Stage II
  • NSCLC, Stage IIIA
  • Erlotinib
  • Goyang-si, Gyeonggi-do, Korea, Republic of
    National Cancer Center
Apr 4, 2022

Non Small Cell Lung Cancer Trial in United States (SNDX-275, erlotinib)

Completed
  • Non Small Cell Lung Cancer
  • Duarte, California
  • +11 more
Apr 25, 2022

NSCLC Trial in New Haven, Farmington (KD019, Erlotinib)

Terminated
  • Carcinoma, Non-Small-Cell Lung
  • New Haven, Connecticut
  • +1 more
May 9, 2022

Lung Cancer, Nonsmall Cell Trial in Lebanon (IRX4204, erlotinib)

Suspended
  • Lung Cancer, Nonsmall Cell
  • Lebanon, New Hampshire
    Geisel School of Medicine at Dartmouth
Mar 29, 2022

Biliary Tract Cancer Trial in Seoul (Pemetrexed 500 MG, Erlotinib)

Recruiting
  • Biliary Tract Cancer
  • Pemetrexed 500 MG
  • Erlotinib
  • Seoul, Korea, Republic of
  • +1 more
Jun 13, 2022

NSCLC Trial in United States (bevacizumab, Erlotinib)

Completed
Has Results
  • Carcinoma, Non-Small-Cell Lung
  • Galloway, New Jersey
  • +6 more
Jun 17, 2022

Cirrhosis, Hepatocellular Carcinoma Trial in United States (Erlotinib, Erlotinib Hydrochloride, Laboratory Biomarker Analysis)

Active, not recruiting
Has Results
  • Cirrhosis
  • Hepatocellular Carcinoma
  • Erlotinib
  • +3 more
  • Jacksonville, Florida
  • +5 more
Feb 24, 2022

NSCLC Trial in United States (Erlotinib + Sorafenib, Erlotinib + Placebo)

Completed
Has Results
  • Non-Small Cell Lung Cancer
  • Erlotinib + Sorafenib
  • Erlotinib + Placebo
  • Fort Myers, Florida
  • +15 more
Feb 15, 2022

A Retrospective Pharmacogenomics Research of EGFR-TKIs,Gefitinib

Recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • +4 more
    • Guangzhou, Guangdong, China
      Cancer Center, Sun Yat-sen University
    Oct 25, 2022

    Erlotinib/Gefitinib Combined With Bevacizumab in Advanced

    Recruiting
    • Non Small Cell Lung Cancer
    • Erlotinib/Gefitinib combined with Bevacizumab
    • Changsha, Hunan, China
      Hunan Provincal Tumor Hospital
    Mar 1, 2022

    Head Neck Cancer Trial in Houston (drug, other, behavioral)

    Active, not recruiting
    • Head and Neck Cancer
    • Houston, Texas
      University of Texas MD Anderson Cancer Center
    Jan 31, 2022

    NSCLC Trial in United States (erlotinib, bemcentinib)

    Completed
    • Non-Small Cell Lung Cancer
    • Los Angeles, California
    • +9 more
    Aug 16, 2022

    Carcinoma, Non-Small Cell Lung, EGFR Gene Mutation Trial in Changsha (Gemcitabine platinum combined with erlotinib)

    Recruiting
    • Carcinoma, Non-Small Cell Lung
    • EGFR Gene Mutation
    • Gemcitabine platinum combined with erlotinib
    • Changsha, Hunan, China
      Hunan Province Tumor Hospital
    Feb 28, 2022

    Recurrent NSCLC Trial in Sacramento, San Francisco (INC280, erlotinib HCl)

    Completed
    • Recurrent Non-small Cell Lung Cancer
    • Sacramento, California
    • +1 more
    Oct 11, 2021

    Cirrhosis, Liver Trial (Erlotinib Hydrochloride)

    Not yet recruiting
    • Cirrhosis, Liver
    • Erlotinib Hydrochloride
    • (no location specified)
    Aug 23, 2021

    NSCLC, EGFR Gene Mutation, EGFR-TKI Resistant Mutation Trial (Nintedanib, gefitinib, erlotinib, afatinib)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • +2 more
    • Nintedanib, gefitinib, erlotinib, afatinib
    • (no location specified)
    Oct 2, 2023

    Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v6 and v7 Trial in

    Active, not recruiting
    • Metastatic Pancreatic Adenocarcinoma
    • +3 more
    • Nashville, Tennessee
      Vanderbilt University/Ingram Cancer Center
    Dec 15, 2021

    Brain and CNS Tumors Trial in Australia, United States (Induction Chemotherapy, Low-Risk Therapy, High-Risk Therapy)

    Active, not recruiting
    Has Results
    • Brain and Central Nervous System Tumors
    • Induction Chemotherapy
    • +3 more
    • Palo Alto, California
    • +5 more
    Nov 29, 2022

    NSCLC Trial in Worldwide (Erlotinib, Docetaxel)

    Completed
    Has Results
    • Carcinoma, Non-Small-Cell Lung
    • Wien, Austria
    • +31 more
    Aug 23, 2022